Clinical trials: Amyloid Beta Protein
Cognitive Dysfunction, Alzheimer Disease
Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults
BACKGROUND Cognitive decline in older adults, especially those who develop Mild Cognitive Impairment and Alzheimer's Disease, currently has limited options of pharmacological treatments, with modest efficacy.
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- NCT06733714
- Testing
- Transcranial Alternating Current Stimulation, Digital Cognitive Training
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio de Janeiro
Alzheimer's Disease
Modeling the Relationships Between Functional Connectivity and Amyloid Deposition in Alzheimer's Disease
Glucose is the main energy source of brain. Different neural degenerative diseases such as Parkinson's disease or Alzheimer's disease have shown distinct brain glucose metabolic patterns.
- Trial name
- NCT04174287
- Testing
- F-18-AV45
- Where
- Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Alzheimer Disease
Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects
Purpose: The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography…
- Trial name
- AV151 (NCT00605046)
- Testing
- SPECT scan
- Where
- 2 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
This research will look at how the brain may change in people with Alzheimer disease (AD). The purpose of this research is to find out whether changes in the brain in people with Alzheimer disease can be detected using a brain…
- Trial name
- MNI-558 (NCT01217021)
- Testing
- [18F] MNI-558
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease
Effect of Lithium and Divalproex in Alzheimer's Disease
This study will examine the effect of the drugs lithium and divalproex (Depakote) on tau proteins, a type of protein in the brain and spinal fluid that are altered in patients with Alzheimer's disease.
- Trial name
- NCT00088387
- Testing
- Divalproex, Lithium
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Alzheimer Disease
Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513
The purpose of the study is to evaluate the efficacy and safety of MNI-513 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer's disease compared to healthy volunteers.
- Trial name
- NCT01000870
- Testing
- MNI-513-01
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Parkinson Disease, Neurological Disorders
Amyloid Beta and Cognition in Parkinson Disease
The investigators propose to study persons with Parkinson Disease (PD) with detailed clinical, cognitive and imaging at the time of study entry and repeat these assessments 2 years later.
- Trial name
- NCT01754168
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Michigan
Mild Cognitive Impairment
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease…
- Trial name
- CEDAR (NCT02646982)
- Testing
- Candesartan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Emory University
Alzheimer Disease
The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease
The purpose of this study is to determine whether short-term use of the drugs ibuprofen and lovastatin affects levels of a protein called beta-amyloid in people who are at risk for developing Alzheimer's Disease (AD).
- Trial name
- NCT00046358
- Testing
- Lovostatin, Ibuprofen
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Alzheimers Disease
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
The underlying goal of this study is to assess 123-I AV39 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
- Trial name
- NCT00439010
- Testing
- [123I] AV 39
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer's Disease
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's disease (AD).
- Trial name
- NCT05463731
- Testing
- Remternetug (IV), Remternetug (SC)
- Where
- 76 sites in United States, Japan
- Volunteers
- 1,667 people
- Sponsor
- Eli Lilly and Company
Preclinical Alzheimer's Disease, Alzheimer Disease
AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease
This Phase 2 study will evaluate the safety, tolerability, immunogenicity, and amyloid-lowering effect of AV-1959R in cognitively unimpaired adults with preclinical Alzheimer's disease.
- Trial name
- AREVIA (NCT07827768)
- Testing
- AV-1959R
- Volunteers
- 160 people
- Sponsor
- Institute for Molecular Medicine
Alzheimer Disease
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-330, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT)…
- Trial name
- NCT00657813
- Testing
- MNI-330 as a brain SPECT tracer of Beta-Amyloid
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Down Syndrome, Amyloid Beta-protein
Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
To determine the sensitivity of the visual assessment of BAY94-9172 PET images in detecting cerebral β-amyloid in individuals with Down Syndrome (DS) and specificity in individuals without DS.
- Trial name
- NCT00928304
- Testing
- Florbetaben (BAY94-9172)
- Where
- 2 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer's Disease
Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease
The purpose of this Phase I study is to determine whether the vaccine (UB 311), targeting the amyloid beta peptide (N-terminal amino acids, 1-14), is safe and immunogenic in patients diagnosed with mild or moderate Alzheimer's…
- Trial name
- NCT00965588
- Testing
- UB 311
- Where
- 2 sites in Taiwan
- Volunteers
- 19 people
- Sponsor
- United Biomedical
Alzheimer Disease, Dementia
Investigating the Impact of Alzheimer's Disease Diagnostics in British Columbia
The 'Investigating the Impact of Alzheimer's Disease Diagnostics in British Columbia' (IMPACT-AD BC) study is an observational, longitudinal cohort study that will examine the impact of cerebrospinal fluid (CSF) testing for core…
- Conditions
- Alzheimer Disease, Dementia, Cognitive Impairment, Mild Cognitive Impairment
- Trial name
- IMPACT-AD BC (NCT05002699)
- Testing
- Alzheimer's disease CSF biomarkers
- Where
- 4 sites in Canada
- Volunteers
- 120 people
- Sponsor
- University of British Columbia
Alzheimer's Disease
Effect of LY2062430 on the Progression of Alzheimer's Disease
Alzheimer's disease (AD) is an age-related degenerative disorder of the brain, characterized by progressive decline in cognitive function and ability to perform activities of daily living, and ultimately can lead to death due to…
- Trial name
- EXPEDITION (NCT00905372)
- Testing
- LY2062430
- Where
- 85 sites in United States, Argentina and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
The underlying goal of this study is to assess 123-I MNI-168 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of Alzheimer's Disease (AD) research participants and similarly aged and gender matched healthy…
- Trial name
- NCT00870519
- Testing
- I-123-MNI-168, 123-I MNI-168
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Prostate Cancer
Predicting Cognitive Decline From Androgen Deprivation Therapy
Androgen Deprivation Therapy (ADT) is associated with cognitive impairment and dementia in men with prostate cancer. Pre-clinical data suggest that ADT-induced hypogonadism leads to accumulation of beta-amyloid plaques in the…
- Trial name
- ABC (NCT05820932)
- Testing
- Blood-based assay, Cognitive assessments, Quality of Life Surveys
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Francisco
Disseminated Sclerosis
A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).
In multiple sclerosis (MS) sub cortical cognitive impairments are frequently reported. Nevertheless, cortical cognitive troubles, with hippocampic memory troubles have been described.
- Trial name
- BioCogS (NCT00978536)
- Testing
- Cognitive impairment of multiple sclerosis
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Nantes University Hospital